Daniel Ermann
Hematologist/oncologist and Associate Professor at Huntsman Cancer Institute, University of Utah, specializing in chronic lymphocytic leukemia (CLL) and lymphoma.
5
APPEARANCES
3
PODCASTS
Sep 7, 2026
Daniel ErmannGUEST
He had some of the most extensive lymphadenopathy I'd ever seen in a patient, above and below the diaphragm.
Daniel ErmannGUEST
He had absolutely no B symptoms, no weight loss, but had a packed marrow greater than 95% involvement.
Daniel ErmannGUEST
And he had more of the SLL phenotype with a white blood cell count of 15, hemoglobin 14, platelets of 170,000.
Daniel ErmannGUEST
And he had very bulky lymph nodes, but all the SUVs were low and I was not concerned for Richter's.
Daniel ErmannGUEST
He had some of the most extensive lymphadenopathy I'd ever seen in a patient, above and below the diaphragm.
Daniel ErmannGUEST
He had absolutely no B symptoms, no weight loss, but had a packed marrow greater than 95% involvement.
Daniel ErmannGUEST
And he had more of the SLL phenotype with a white blood cell count of 15, hemoglobin 14, platelets of 170,000.
Daniel ErmannGUEST
And he had very bulky lymph nodes, but all the SUVs were low and I was not concerned for Richter's.
Daniel ErmannGUEST
He had some of the most extensive lymphadenopathy I'd ever seen in a patient, above and below the diaphragm.
Daniel ErmannGUEST
He had absolutely no B symptoms, no weight loss, but had a packed marrow greater than 95% involvement.
Daniel ErmannGUEST
And he had more of the SLL phenotype with a white blood cell count of 15, hemoglobin 14, platelets of 170,000.
Daniel ErmannGUEST
And he had very bulky lymph nodes, but all the SUVs were low and I was not concerned for Richter's.
Neil LoveHOST
We begin with Dr. Irmen, who has a young patient who elected to participate in a clinical trial of upfront management of CLL.
Daniel ErmannGUEST
He was Rai stage one and was found to have progressive cervical lymphadenopathy.
Daniel ErmannGUEST
His CLL was IGHV mutated with trisomy twelve, deletion thirteen Q complex karyotype.
Daniel ErmannGUEST
His complex karyotype actually fit with one of the few more favorable prognostic factors given he had a trisomy nineteen.
Neil LoveHOST
We begin with Dr. Urman, who has a young patient who elected to participate in a clinical trial of upfront management of CLL.
Daniel ErmannGUEST
He was Rai stage one and was found to have progressive cervical lymphadenopathy.
Daniel ErmannGUEST
His CLL was IGHV mutated with trisomy twelve, deletion thirteen Q complex karyotype.
Daniel ErmannGUEST
So he actually had his complex karyotype actually fit with one of the few more favorable prognostic factors given he had a trisomy nineteen.
Daniel ErmannGUEST
But regardless, he eventually did develop progressive fatigue, anemia, and worsening lymphadenopathy, unintentional weight loss, meeting treatment criteria.